Suvendu Lomash

Suvendu Lomash has a diverse range of work experience in the field of protein engineering and antibody discovery. Suvendu is currently working at NextCure, Inc. as a Scientist III, leading a team in developing engineered antibodies and immunocytokines for checkpoint immunotherapy in cancer. Suvendu'sresponsibilities include conceptualization and development of bispecific/fusion protein formats, as well as extensive experience with mammalian cell expression and purification. Prior to this role, Suvendu worked as a Scientist II at NextCure, Inc., where they led and completed three monoclonal antibody discovery projects and implemented molecular modeling techniques for mAb humanization.

Before joining NextCure, Inc., Suvendu worked at the National Institutes of Health (NIH): Intramural Research Program (IRP) as a Research Fellow and Visiting Fellow. During their time at NIH, they conducted research on the characterization of a mammalian brain protein called TMEM266, analyzing its structure, function, and molecular interactions. Suvendu also studied the structural basis of glutamate receptor activation by different ligands, utilizing crystallography and ligand-binding assays. Suvendu has contributed to publications and has broad experience in molecular modeling, microscopy, and protein purification.

In addition, Suvendu has worked as a Research Associate at the National Institute of Immunology (NII), where they gained experience in immunology research.

Overall, Suvendu Lomash has a strong background in protein engineering, antibody discovery, and molecular biology, with expertise in diverse techniques and methodologies used in the field.

Suvendu Lomash pursued their Bachelor's degree in Human Biology from the All India Institute of Medical Sciences from 1998 to 2001. After completing their Bachelor's degree, they went on to complete their Master's degree in Biotechnology from the same institute from 2001 to 2003. Following their Master's degree, Suvendu Lomash pursued a Ph.D. in Structural Biology and Immunology from the National Institute of Immunology from 2003 to 2009.